Jpmorgan Chase & CO Entrada Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 10,570 shares of TRDA stock, worth $187,828. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,570
Previous 8,413
25.64%
Holding current value
$187,828
Previous $119,000
26.05%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding TRDA
# of Institutions
89Shares Held
27.8MCall Options Held
100Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$86.5 Million0.92% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$78.6 Million34.63% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$78.3 Million29.39% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.13MShares$55.7 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$30.1 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $557M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...